PEGASUS-2: Personalized Genomics for Prenatal Abnormalities Screening Using Maternal Blood: Towards first-tier screening and beyond

Principal Investigator: François Rousseau, Sylvie Langlois
Theme : Health
Competition : 2017 Large-Scale Applied Research Project Competition Genomics and Precision Health
Status : In progress
Start : Apr. 1, 2018
End: Mar. 31, 2022
Budget : $12,241,625.00



The discovery that fetal DNA is present in the mother’s blood during pregnancy has led to the development of a genomics-based maternal blood test called NIPS (non-invasive prenatal screening), which is a very reliable test for Down syndrome. In part due to its cost, NIPS is currently only used as a second-tier test, after a mother has tested positive on less costly and less accurate tests, to confirm the finding prior to resorting to amniocentesis.

 

Making NIPS the entry-level test for Down syndrome could benefit women by more accurately detecting an affected pregnancy with less chance of a false positive result and by providing that result several weeks earlier in the pregnancy. As well, because NIPS can detect other chromosomal abnormalities, its use could enable screening for more conditions. The PEGASUS-2 project’s goal is to provide high-quality evidence to support the use of NIPS instead of traditional screening tests by comparing its use as a first-tier and second-tier test in a large cohort of pregnant women. The project will also study the cost effectiveness of expanding screening to other conditions and the ethical, social and legal implications of doing so. It will also provide strategies to promote shared decision-making between couples and health-care professionals. Finally, it will further develop the NIPS technology to reduce its costs by 50 percent and expand its ability to detect other anomalies, as well as ensuring quality control for clinical NIPS testing in Canada and worldwide.

 

PEGAGUS-2 will enable publicly funded access to a promising genomics technology for all interested pregnant women, while ensuring that couples have access to web-based tools to help their decision-making and that all health-care professionals are trained in shared decision-making for prenatal screening.

 

Short version                 

PEGAGUS-2 will provide the evidence needed to support the provision of a genomics-based prenatal screening test for Down syndrome as a first-tier test and to expand it to diagnose other chromosomal anomalies. Its work will enable earlier and more accurate detection of fetal chromosomal anomalies and support shared decision-making between couples and their health-care professionals.

 

To learn more about this project, click here


Lead Genome Centre: Génome Québec

Co-lead Genome Centre: Genome British Columbia

 

Co-investigators and Users:

Daniel Reinharz Université Laval
Vardit Ravitsky Université de Montréal
France Légaré Université Laval
Brenda Wilson University of Ottawa
Chris McCabe University of Alberta
Jason Robert Université Laval
Timothy Caulfield University of Alberta
Anne-Marie Laberge Université de Montréal
Aly Karsan University of British Columbia
Guy Rouleau Université McGill
Jean-Claude Forest Université Laval
Julian Little University of Ottawa 
François Audibert  Université de Montréal 
Jacques Michaud  Université de Montréal
Anik Giguère Université Laval 
R. Douglas Wilson University of Calgary
Yves Giguère Université Laval
Luo Wei Public Health Agency of Canada
Ross Duncan Public Health Agency of Canada
Christian Gagné Université Laval
Jean Longtin Institut national de santé publique du Québec
Maud Vallée Institut national de santé publique du Québec
Mathieu Ouimet Université Laval
Michèle de Guise Institut national d'excellence en santé et services sociaux du Québec 
Jane Evans University of Manitoba
Jan Friedman University of British Columbia
William McKellin University of British Columbia
Mark Walker University of Ottawa
Mario Pazzagli University of Florence, Italy
Elisabetta Pelo AOU Careggi, Florence, Italy
Joris Vermeesch UZ Leuven, Belgium
Michel Vekemans Hôpital Necker, Paris, France
Isabelle Lévesque Université Laval
Hilary Bekker University of Leeds, United Kingdom